Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up – Here’s Why

Corcept Therapeutics Incorporated (NASDAQ:CORT)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $36.31, but opened at $41.51. Corcept Therapeutics shares last traded at $41.2310, with a volume of 2,669,408 shares changing hands.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase 3 ROSELLA met its overall survival primary endpoint in platinum‑resistant ovarian cancer — a clear clinical success that materially improves relacorilant’s value thesis and is the main driver of the move. Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
• Positive Sentiment: Multiple trade and analyst outlets reported the OS win, reinforcing market confidence that the drug could drive future revenue and partnership interest. CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
• Positive Sentiment: Wall‑street coverage (e.g., Reuters) flagged the late‑stage success, increasing visibility with institutional investors and media, which can amplify buying interest. Corcept’s cancer drug meets main goal in late-stage trial
• Positive Sentiment: Analyst optimism picked up: Canaccord raised its price target to $100 and maintained a buy rating, signaling upside potential versus the current price and likely supporting additional demand. CORT Corcept Therapeutics price target raised by Canaccord
• Neutral Sentiment: Options flow shows elevated activity: about 4,870 put contracts were purchased (≈78% above the typical daily put volume), indicating some investors are hedging or speculating on near‑term volatility rather than a clear directional consensus. (No external link)
• Negative Sentiment: Regulatory and legal overhangs remain — shareholder law firms (Hagens Berman and Pomerantz) launched investigations tied to the company’s prior FDA complete response letter for relacorilant in Cushing’s syndrome and the sharp December sell‑off, which could lead to litigation costs or disclosure risk. CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
• Negative Sentiment: Remember the December FDA complete response letter for relacorilant (Cushing’s syndrome) that previously drove a large share price drop — regulatory uncertainty remains a material risk even after the oncology win. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated – CORT

Wall Street Analysts Forecast Growth

CORT has been the subject of a number of recent research reports. Canaccord Genuity Group lifted their price target on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research report on Friday. Truist Financial set a $50.00 target price on shares of Corcept Therapeutics in a report on Wednesday, December 31st. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. HC Wainwright raised their price objective on Corcept Therapeutics from $90.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective for the company. in a research note on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $83.50.

Corcept Therapeutics Price Performance

The firm has a 50-day moving average of $65.24 and a 200 day moving average of $71.10. The company has a market capitalization of $4.63 billion, a PE ratio of 49.98 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The company had revenue of $207.64 million for the quarter, compared to analysts’ expectations of $223.78 million. During the same period in the previous year, the business earned $0.41 EPS. The business’s revenue was up 13.8% compared to the same quarter last year. As a group, research analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Insider Activity at Corcept Therapeutics

In related news, insider Joseph Douglas Lyon sold 5,000 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $79.53, for a total transaction of $397,650.00. Following the completion of the sale, the insider owned 10,277 shares in the company, valued at approximately $817,329.81. This represents a 32.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joseph K. Belanoff sold 40,000 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $79.77, for a total value of $3,190,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,701,370 shares in the company, valued at approximately $215,488,284.90. This represents a 1.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 194,500 shares of company stock valued at $14,186,410 in the last quarter. 20.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Corcept Therapeutics

Several hedge funds have recently bought and sold shares of CORT. Pathstone Holdings LLC grew its stake in shares of Corcept Therapeutics by 0.8% during the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after acquiring an additional 144 shares during the period. Huntington National Bank lifted its holdings in Corcept Therapeutics by 54.0% during the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 168 shares in the last quarter. Campbell Newman Asset Management Inc. boosted its position in shares of Corcept Therapeutics by 0.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after purchasing an additional 170 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Corcept Therapeutics by 1.8% in the second quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock worth $730,000 after purchasing an additional 180 shares during the period. Finally, Clearstead Advisors LLC increased its stake in shares of Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 193 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.